mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2025-16-4-28-34mvjr-2076Research ArticleПСИХИАТРИЯPSYCHIATRYКлинико-генетические ассоциации депрессивных симптомов при параноидной шизофренииClinical and genetic associations of depressive symptoms in paranoid schizophreniahttps://orcid.org/0000-0001-6679-4454СултановаР. И.SultanovaR. I.

Султанова Рената Ильдаровна, врач-психиатр

Москва

Renata I. Sultanova, psychiatrist

Moscow

renatasu@mail.ruhttps://orcid.org/0000-0001-9944-141XГашкаримовВ. Р.GashkarimovV. R.

Гашкаримов Вадим Римович, врач-психиатр

Уфа

Vadim R. Gashkarimov, psychiatrist

Ufa

gashkarimov@yandex.ruhttps://orcid.org/0000-0003-4516-3324ГасенкоК. А.GasenkoK. A.

Гасенко Ксения Александровна, врач-психиатр, заведующая отделением

Омск

Gasenko A. Ksenia, psychiatrist, head of the department 

Omsk

ksenia.gasenko@yandex.ruhttps://orcid.org/0000-0002-9994-8656ЕфремовИ. С.EfremovI. S.

Ефремов Илья Сергеевич, к.м.н., врач-психиатр, психотерапевт, куратор психологического центра

Уфа

Ilya S. Efremov, Cand. Sci. (Med.), psychiatrist, psychotherapist, curator

Ufa

efremovilya@gmail.comhttps://orcid.org/0000-0001-7148-4485АсадуллинА. Р.AsadullinA. R.

Асадуллин Азат Раилевич, д.м.н., профессор кафедры психиатрии, наркологии и психотерапии; директор центра молекулярной медицины; ведущий научный сотрудник института персонализированной психиатрии и неврологии; профессор кафедры психиатрии, наркологии, психотерапии и клинической психологии; профессор кафедры Психиатрии и наркологии

Санкт-Петербург; Уфа; Саратов; Ташкент

Azat R. Asadullin, Dr. Sci. (Med.), Professor, Department of Psychiatry, Narcology and Psychotherapy; Director of the Center for Molecular medicine; Leading Researcher; Professor, Department of Psychiatry, Narcology, Psychotherapy and clinical psychology; Professor of the Department of Psychiatry and Narcology

Saint Petersburg; Ufa; Saratov; Tashkent

droar@yandex.ruЧайка-СитиРоссияChaika-CityRussian FederationРеспубликанская клиническая психиатрическая больницаРоссияRepublican Clinical Psychiatric HospitalRussian FederationКлиническая психиатрическая больница им. Н.Н. СолодниковаРоссияN.N. Solodnikov Clinical Psychiatric HospitalRussian FederationМастерская психотерапииРоссияPsychotherapy WorkshopRussian FederationНациональный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева; Башкирский государственный медицинский университет; Уфимский университет науки и технологий; Саратовский государственный медицинский университет им. В.И. Разумовского; Ташкентская Медицинская АкадемияРоссияV.M. Bekhterev National Medical Research Center of Psychiatry and Neurology; Bashkir State Medical University; Ufa University of Science and Technology; Saratov State Medical University named after V.I. Razumovsky; Tashkent Medical AcademyRussian Federation2025211220251642834Copyright © Султанова Р.И., Гашкаримов В.Р., Гасенко К.А., Ефремов И.С., Асадуллин А.Р., 20252025Султанова Р.И., Гашкаримов В.Р., Гасенко К.А., Ефремов И.С., Асадуллин А.Р.Sultanova R.I., Gashkarimov V.R., Gasenko K.A., Efremov I.S., Asadullin A.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/2076

Цель: установить клинико-генетические ассоциации у пациентов параноидной формой шизофрении с депрессивными проявлениями и без таковых. Материалы и методы: были включены пациенты с параноидной шизофренией после 10–14-ого дня стационарного лечения. Использовались психометрические методы: шкала депрессии Калгари у больных с шизофренией (CDSS), шкала PANSS, Колумбийская шкала оценки суицидального риска (C-SSRS). Генотипирование гена HTR2A (rs6313) проводилось ПЦР. Статистические методы: Microsoft Excel, IBM SPSS Statistics 26. Результаты: у 31,8% (124/390) были выявлены депрессивные проявления. Реже всех была встречаемость пункта «суицид», однако именно он был выражен сильнее всего в тяжёлой степени. Выводы: у 31,8% респондентов с параноидной шизофренией имелись депрессивные проявления. Выявлена обратная зависимость между тяжестью состояния и частотой встречаемости депрессивных проявлений: наиболее распространённым было отсутствие симптомов, реже всего встречалась тяжелая степень. Безнадёжность продемонстрировала связь с геном HTR2A rs6313 (р=0,044). При сопоставлении остальных значений по шкале Калгари значимых корреляционных связей выявлено не было.

Objective: to establish clinical and genetic associations in patients with paranoid schizophrenia with and without depressive manifestations. Materials and methods: patients with paranoid schizophrenia after 10–14 days of inpatient treatment were included. Psychometric methods were used: Calgary Depression Scale for Patients with Schizophrenia (CDSS), PANSS scale, Columbia Suicide Risk Rating Scale (C-SSRS). Genotyping of the HTR2A gene (rs6313) was performed by PCR. Statistical methods: Microsoft Excel, IBM SPSS Statistics 26. Results: depressive manifestations were detected in 31.8% (124/390). The least frequent item was “suicide”, but it was expressed most strongly in a severe degree. Conclusions: 31.8% of respondents with paranoid schizophrenia experienced depressive symptoms. An inverse relationship was found between the severity of the condition and the frequency of depressive symptoms: the most common was the absence of symptoms, while severe symptoms were the least common. Hopelessness demonstrated an association with the HTR2A rs6313 gene (p=0.044). No significant correlations were found when comparing the remaining values on the Calgary Depression Scale.

шизофрениядепрессивные симптомыгенетические ассоциацииschizophreniadepressive symptomsgenetic associationsИсследование не имело спонсорской поддержки.The study did not have sponsorship.ReferencesAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Publishing; 2013. https://doi.org/10.1176/appi.books.9780890425596American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Publishing; 2013. https://doi.org/10.1176/appi.books.9780890425596ICD-11 for mortality and morbidity statistics. 2018. URL: https://icd.who.int/browse/2018/mms/enICD-11 for mortality and morbidity statistics. 2018. URL: https://icd.who.int/browse/2018/mms/enSiris SG, Bench C. Depression and schizophrenia. In: Schizophrenia. 2003. 4. Остроглазов В.Г. Маскированная депрессия в амбулаторно-поликлинической практике в общеймедицинской сети. Журнал неврологии и психиатрии им. С.С. Корсакова. 1979;79(4):438–444.Siris SG, Bench C. Depression and schizophrenia. In: Schizophrenia. 2003.Мазо Г.Э., Ганзенко М.А., Рукавишников Г.В., Касьянов Е.Д. Депрессия при шизофрении: подходы к терапии: методические рекомендации. НМИЦ ПН им. В.М. Бехтерева; 2020.Ostroglazov VG. Masked depression in outpatient facilities of the general medical health network. S.S. Korsakov J Neurol Psychiatry. 1979;79(4):438-44. (In Russ.).Hettige NC, Bani-Fatemi A, Sakinofsky I, De Luca V. A biopsychosocial evaluation of the risk for suicide in schizophrenia. CNS Spectr. 2018;23(4):253-263. https://doi.org/10.1017/S1092852917000128Mazo G.E.,. Ganzenko M.A, Rukavishnikov G.V., Kas'yanov E.D. Depressiya pri shizofrenii: podkhody k terapii: metodicheskie rekomendatsii. NMITs PN im. V.M. Bekhtereva. 2020. (In Russ.). https://bekhterev.ru/wp-content/uploads/2021/05/04-mr2020-mazo-i-soavt.pdfНасырова Р.Ф., Шнайдер Н.А., Миронов К.О., Шипулин Г.А., Дрибноходова О.П., и др. Фармакогенетика шизофрении в реальной клинической практике: клинический случай. Неврология, нейропсихиатрия, психосоматика. 2018;10(4):88-93.Hettige NC, Bani-Fatemi A, Sakinofsky I, De Luca V. A biopsychosocial evaluation of the risk for suicide in schizophrenia. CNS Spectr. 2018;23(4):253-263. https://doi.org/10.1017/S1092852917000128van Rooijen G, Vermeulen JM, Ruhé HG, de Haan L. Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2019;24(2):239-248. https://doi.org/10.1017/S1092852917000554Nasyrova R.F., Schnaider N.A., Mironov K.O., Shipulin G.A., Dribnokhodova O.P., et al. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):88-93. (In Russ.) https://doi.org/10.14412/2074-2711-2018-4-88-93Naguy A. Depression in schizophrenia - A good or bad omen? Asia Pac Psychiatry. 2018;10(2):e12312. https://doi.org/10.1111/appy.12312van Rooijen G, Vermeulen JM, Ruhé HG, de Haan L. Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2019;24(2):239-248. https://doi.org/10.1017/S1092852917000554Мосолов С.Н., Цукарзи Э.Э. Психофармакотерапия шизофрении. В кн.: Психиатрия: национальное руководство. 2018. Mosolov SN, Tsukarzi EE. Psychopharmacotherapy of schizophrenia. In: Psihiatriya: nacional'noe rukovodstvo. 2018. (In Russ.).Naguy A. Depression in schizophrenia - A good or bad omen? Asia Pac Psychiatry. 2018;10(2):e12312. https://doi.org/10.1111/appy.12312Маслеников Н., Цукарзи Э., Мосолов С. Алгоритм биологической терапии депрессии при шизофрении. Современная Терапия Психических Расстройств, 2019;(2):31–40.Mosolov SN, Tsukarzi EE. Psychopharmacotherapy of schizophrenia. In: Psihiatriya: nacional'noe rukovodstvo. 2018. (In Russ.).Edwards CJ, Garety P, Hardy A. The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis. Psychol Med. 2019;49(15):2486-2498. https://doi.org/10.1017/S0033291719002381Maslenikov N., Tsukarzi E., Mosolov S. Algorithm of Biological Treatment for Depression in Schizophrenia. Current Therapy of Mental Disorders. 2019;(2):31–40. (In Russ.) https://doi.org/10.21265/PSYPH.2019.34.92.005Guessoum SB, Le Strat Y, Dubertret C, Mallet J. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109862. https://doi.org/10.1016/j.pnpbp.2020.109862Edwards CJ, Garety P, Hardy A. The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis. Psychol Med. 2019;49(15):2486-2498. https://doi.org/10.1017/S0033291719002381Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020;16:519-534. https://doi.org/10.2147/NDT.S225643Guessoum SB, Le Strat Y, Dubertret C, Mallet J. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109862. https://doi.org/10.1016/j.pnpbp.2020.109862Krynicki CR, Upthegrove R, Deakin JFW, Barnes TRE. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand. 2018;137(5):380-390. https://doi.org/10.1111/acps.12873Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020;16:519-534. https://doi.org/10.2147/NDT.S225643Demyttenaere K, Anthonis E, Acsai K, Correll CU. Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. Front Psychiatry. 2022;13:795866. https://doi.org/10.3389/fpsyt.2022.795866Krynicki CR, Upthegrove R, Deakin JFW, Barnes TRE. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand. 2018;137(5):380-390. https://doi.org/10.1111/acps.12873Xu J, Jiao Y, Xing M, Lin Y, Su Y, et al. Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia. Gen Psychiatr. 2018;31(3):e100018. https://doi.org/10.1136/gpsych-2018-100018Demyttenaere K, Anthonis E, Acsai K, Correll CU. Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. Front Psychiatry. 2022;13:795866. https://doi.org/10.3389/fpsyt.2022.795866Henriksen MG, Nordgaard J, Jansson LB. Genetics of Schizophrenia: Overview of Methods, Findings and Limitations. Front Hum Neurosci. 2017;11:322. https://doi.org/10.3389/fnhum.2017.00322Xu J, Jiao Y, Xing M, Lin Y, Su Y, et al. Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia. Gen Psychiatr. 2018;31(3):e100018. https://doi.org/10.1136/gpsych-2018-100018Fang X, Chen Y, Wang Y, Ren J, Zhang C. Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109673. https://doi.org/10.1016/j.pnpbp.2019.109673Henriksen MG, Nordgaard J, Jansson LB. Genetics of Schizophrenia: Overview of Methods, Findings and Limitations. Front Hum Neurosci. 2017;11:322. https://doi.org/10.3389/fnhum.2017.00322Shkundin A, Halaris A. Associations of BDNF/BDNF-AS SNPs with Depression, Schizophrenia, and Bipolar Disorder. J Pers Med. 2023;13(9):1395. https://doi.org/10.3390/jpm13091395Fang X, Chen Y, Wang Y, Ren J, Zhang C. Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109673. https://doi.org/10.1016/j.pnpbp.2019.109673Lu G, Li J, Zhang H, Zhao X, Yan LJ, Yang X. Role and Possible Mechanisms of Sirt1 in Depression. Oxid Med Cell Longev. 2018;2018:8596903. https://doi.org/10.1155/2018/8596903Shkundin A, Halaris A. Associations of BDNF/BDNF-AS SNPs with Depression, Schizophrenia, and Bipolar Disorder. J Pers Med. 2023;13(9):1395. https://doi.org/10.3390/jpm13091395Wang D, Tang W, Zhao J, Fan W, Zhang Y, Zhang C. A Comprehensive Analysis of the Effect of SIRT1 Variation on the Risk of Schizophrenia and Depressive Symptoms. Front Genet. 2020;11:832. https://doi.org/10.3389/fgene.2020.00832Lu G, Li J, Zhang H, Zhao X, Yan LJ, Yang X. Role and Possible Mechanisms of Sirt1 in Depression. Oxid Med Cell Longev. 2018;2018:8596903. https://doi.org/10.1155/2018/8596903Broniarczyk-Czarniak M, Szemraj J, Śmigielski J, Gałecki P. The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia. Curr Issues Mol Biol. 2022;44(1):336-349. https://doi.org/10.3390/cimb44010025Wang D, Tang W, Zhao J, Fan W, Zhang Y, Zhang C. A Comprehensive Analysis of the Effect of SIRT1 Variation on the Risk of Schizophrenia and Depressive Symptoms. Front Genet. 2020;11:832. https://doi.org/10.3389/fgene.2020.00832Hughes ZH, Hughes LM, Khan SS. Genetic contributions to risk of adverse pregnancy outcomes. Curr Cardiovasc Risk Rep. 2023;17(11):185-193. https://doi.org/10.1007/s12170-023-00729-yBroniarczyk-Czarniak M, Szemraj J, Śmigielski J, Gałecki P. The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia. Curr Issues Mol Biol. 2022;44(1):336-349. https://doi.org/10.3390/cimb44010025Li W. Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study. Schizophr Res Cogn. 2020;23:100193. https://doi.org/10.1016/j.scog.2020.100193Hughes ZH, Hughes LM, Khan SS. Genetic contributions to risk of adverse pregnancy outcomes. Curr Cardiovasc Risk Rep. 2023;17(11):185-193. https://doi.org/10.1007/s12170-023-00729-ySullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187-1192. https://doi.org/10.1001/archpsyc.60.12.1187Li W. Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study. Schizophr Res Cogn. 2020;23:100193. https://doi.org/10.1016/j.scog.2020.100193Peitl V, Štefanović M, Karlović D. Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. Prog Neuropsychopharmacol Biol Psychiatry. 2017;77:209-215. https://doi.org/10.1016/j.pnpbp.2017.04.011Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187-1192. https://doi.org/10.1001/archpsyc.60.12.1187Selvaraj S, Arnone D, Cappai A, Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014;45:233-245. https://doi.org/10.1016/j.neubiorev.2014.06.005Peitl V, Štefanović M, Karlović D. Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. Prog Neuropsychopharmacol Biol Psychiatry. 2017;77:209-215. https://doi.org/10.1016/j.pnpbp.2017.04.011Sher L, Kahn RS. Suicide in Schizophrenia: An Educational Overview. Medicina (Kaunas). 2019;55(7):361. https://doi.org/10.3390/medicina55070361Selvaraj S, Arnone D, Cappai A, Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014;45:233-245. https://doi.org/10.1016/j.neubiorev.2014.06.005Bosanac P, Castle DJ. Schizophrenia and depression. Med J Aust. 2013;199(S6):S36-9. https://doi.org/10.5694/mja12.10516Sher L, Kahn RS. Suicide in Schizophrenia: An Educational Overview. Medicina (Kaunas). 2019;55(7):361. https://doi.org/10.3390/medicina55070361Hayes RD, Chang CK, Fernandes A, Begum A, To D, et al. Associations between symptoms and all-cause mortality in individuals with serious mental illness. J Psychosom Res. 2012;72(2):114-119. https://doi.org/10.1016/j.jpsychores.2011.09.012Bosanac P, Castle DJ. Schizophrenia and depression. Med J Aust. 2013;199(S6):S36-9. https://doi.org/10.5694/mja12.10516Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, et al. Pharmacogenetic Associations of Antipsychotic DrugRelated Weight Gain: A Systematic Review and Metaanalysis. Schizophr Bull. 2016;42(6):1418-1437. https://doi.org/10.1093/schbul/sbw058Hayes RD, Chang CK, Fernandes A, Begum A, To D, et al. Associations between symptoms and all-cause mortality in individuals with serious mental illness. J Psychosom Res. 2012;72(2):114-119. https://doi.org/10.1016/j.jpsychores.2011.09.012Иващенко Д.В., Буромская Н.И., Шиманов П.В., Дейч Р.В., Настович М.И., и др. Полиморфный вариант HTR2A rs6313 ассоциирован с нежелательными реакциями на антипсихотики у подростков с острым психотическим эпизодом. Фарматека, 2021;28(9):45-51Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, et al. Pharmacogenetic Associations of Antipsychotic DrugRelated Weight Gain: A Systematic Review and Metaanalysis. Schizophr Bull. 2016;42(6):1418-1437. https://doi.org/10.1093/schbul/sbw058Massoud S, Salmanian M, Tabibian M, Ghamari R, Tavabe Ghavami TS, Alizadeh F. The contribution of the 5-hydroxytryptamine receptor 2 A gene polymorphisms rs6311 and rs6313 to Schizophrenia in Iran. Mol Biol Rep. 2023;50(3):2633-2639. https://doi.org/10.1007/s11033-022-08222-2Ivashchenko D.V., Buromskaya N.I., Shimanov P.V., Deich R.V., Nastovich M.I., et al. HTR2A rs6313 polymorphic variant is associated with adverse effects to antipsychotics in adolescents with an acute psychotic episode Farmateka. 2021;28(9):45–51. (In Russ.). https://doi.org/10.18565/pharmateca.2021.9.45-51Maffioletti E, Valsecchi P, Minelli A, Magri C, Bonvicini C, et al. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Dev Res. 2020;81(6):754-761. https://doi.org/10.1002/ddr.21686Massoud S, Salmanian M, Tabibian M, Ghamari R, Tavabe Ghavami TS, Alizadeh F. The contribution of the 5-hydroxytryptamine receptor 2 A gene polymorphisms rs6311 and rs6313 to Schizophrenia in Iran. Mol Biol Rep. 2023;50(3):2633-2639. https://doi.org/10.1007/s11033-022-08222-2Maffioletti E, Valsecchi P, Minelli A, Magri C, Bonvicini C, et al. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Dev Res. 2020;81(6):754-761. https://doi.org/10.1002/ddr.2Maffioletti E, Valsecchi P, Minelli A, Magri C, Bonvicini C, et al. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Dev Res. 2020;81(6):754-761. https://doi.org/10.1002/ddr.2

The authors declare that there are no conflicts of interest present.